open access

Ahead of print
Clinical vignette
Published online: 2021-04-28
Submitted: 2021-01-22
Accepted: 2021-02-25
Get Citation

A dream that came true: Poland’s first successful CAR-T cell therapy in child with refractory B-cell acute lymphoblastic leukemia (ALL)

Pawel Marschollek, Karolina Liszka, Ewa Gorczynska, Monika Mielcarek-Siedziuk, Blanka Rybka, Joanna Taha, Krzysztof Kalwak
DOI: 10.5603/AHP.a2021.0028

open access

Ahead of print
CLINICAL VIGNETTE
Published online: 2021-04-28
Submitted: 2021-01-22
Accepted: 2021-02-25

Abstract

When all of the usually applied treatment methods fail, we have to try something innovative. In this vignette, we present the history of the first in Poland CAR-T cell therapy in a child with refractory B-cell acute lymphoblastic leukemia (ALL). In more than 10 months observation time post infusion the patient remains MRD-free with a chance for long awaited clinical cure.

Abstract

When all of the usually applied treatment methods fail, we have to try something innovative. In this vignette, we present the history of the first in Poland CAR-T cell therapy in a child with refractory B-cell acute lymphoblastic leukemia (ALL). In more than 10 months observation time post infusion the patient remains MRD-free with a chance for long awaited clinical cure.

Get Citation

Keywords

CAR-T cell therapy, acute lymphoblastic leukemia

About this article
Title

A dream that came true: Poland’s first successful CAR-T cell therapy in child with refractory B-cell acute lymphoblastic leukemia (ALL)

Journal

Acta Haematologica Polonica

Issue

Ahead of print

Article type

Clinical vignette

Published online

2021-04-28

DOI

10.5603/AHP.a2021.0028

Keywords

CAR-T cell therapy
acute lymphoblastic leukemia

Authors

Pawel Marschollek
Karolina Liszka
Ewa Gorczynska
Monika Mielcarek-Siedziuk
Blanka Rybka
Joanna Taha
Krzysztof Kalwak

References (8)
  1. Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018; 378(5): 439–448.
  2. Cope S, Ayers D, Zhang J, et al. Integrating expert opinion with clinical trial data to extrapolate long-term survival: a case study of CAR-T therapy for children and young adults with relapsed or refractory acute lymphoblastic leukemia. BMC Med Res Methodol. 2019; 19(1): 182.
  3. Diorio C, Maude SL. CAR T cells vs allogeneic HSCT for poor-risk ALL. Hematology Am Soc Hematol Educ Program. 2020; 2020(1): 501–507.
  4. Styczyński J. Where dreams come true: CAR-T cell therapy in Poland! Acta Haematologica Polonica. 2020; 51(1): 1.
  5. Dytfeld D, Łojko-Dankowska A, Matuszak M, et al. Road to clinical implementation of CAR-T technology in Poznań. Acta Haematologica Polonica. 2020; 51(1): 24–28.
  6. Styczyński J. A brief history of CAR-T cells: from laboratory to the bedside. Acta Haematologica Polonica. 2020; 51(1): 2–5.
  7. Gil L, Łojko-Dankowska A, Matuszak M, et al. CAR-T cell therapy — toxicity and its management. Acta Haematologica Polonica. 2020; 51(1): 6–10.
  8. Styczyński J. Infections following CAR-T cells therapy: current state-of-the-art review and recommendations. Acta Haematologica Polonica. 2020; 51(1): 11–16.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: journals@viamedica.pl